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Background
Cognitive–behavioural therapy (CBT) is recommended for all
patients with psychosis, but is offered to only a minority. This is
attributable, in part, to the resource-intensive nature of CBT for
psychosis. Responses have included the development of CBT for
psychosis in brief and targeted formats, and its delivery by briefly
trained therapists. This study explored a combination of these
responses by investigating a brief, CBT-informed intervention
targeted at distressing voices (the GiVE intervention) adminis-
tered by a briefly trained workforce of assistant psychologists.
Aims
To explore the feasibility of conducting a randomised controlled
trial to evaluate the clinical and cost-effectiveness of the GiVE
intervention when delivered by assistant psychologists to
patients with psychosis.
Method
This was a three-arm, feasibility, randomised controlled trial
comparing the GiVE intervention, a supportive counselling
intervention and treatment as usual, recruiting across two sites,
with 1:1:1 allocation and blind post-treatment and follow-up
assessments.
Results
Feasibility outcomes were favourable with regard to the
recruitment and retention of participants and the adherence of
assistant psychologists to therapy and supervision protocols. For
the candidate primary outcomes, estimated effects were in
favour of GiVE compared with supportive counselling and treat-
ment as usual at post-treatment. At follow-up, estimated effects
were in favour of supportive counselling compared with GiVE
and treatment as usual, and GiVE compared with treatment as
usual.
Conclusions
A definitive trial of the GiVE intervention, delivered by assistant
psychologists, is feasible. Adaptations to the GiVE intervention
and the design of any future trials may be necessary.
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Approximately 300 000 people in England and Wales have a diag-
nosis of psychosis.1 The overall annual cost of psychosis in
England has been estimated at £11.8 billion.2 Cognitive–behavioural
therapy (CBT) for psychosis is recommended by the National
Institute for Health and Care Excellence (NICE) for the treatment
of psychosis,3 but is offered to only 26% of patients with psychosis.4
One reason for this lack of access is limited resources,5 as CBT for
psychosis is resource-intensive in its duration (minimum of 16 ses-
sions recommended byNICE) and delivery (by highly trained thera-
pists, typically CBT therapists or clinical psychologists), and NICE
has recommended research to explore how resources could be
reduced.3 Our response has been twofold: first, we conducted a
meta-analysis suggesting that CBT for psychosis could effectively
treat the symptoms of psychosis when offered in fewer than 16 ses-
sions;6 and second, consistent with recent developments favouring
the targeting of single psychosis symptoms,7 we developed a brief,
CBT-informed intervention for distressing voice hearing experi-
ences (‘Guided self-help CBT intervention for voices’, referred to
as GiVE). GiVE is a structured and workbook-based intervention8
derived from our self-help book,9 and has the potential to be deliv-
ered by a cost-effective and widely available workforce of psych-
ology graduates (assistant psychologists). We initially evaluated
GiVE when delivered by clinical psychologists, with promising
results.10 Our next step was to explore the efficacy of GiVE when
delivered by assistant psychologists. Before seeking funding for a
definitive randomised controlled trial (RCT), we needed to demon-
strate the feasibility of engaging patients, clinicians, assistant psy-
chologists and service managers in the delivery of such a trial.
The aims of this feasibility study were to assess the acceptability
of GiVE to clinicians and patients, and the ability of assistant psy-
chologists to adhere to therapy and clinical supervision protocols.
An estimate of the standard deviation of outcomes was also
sought to facilitate a sample size calculation for use within a defini-
tive trial.
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Method
Study design
The published study protocol11 is briefly described here. This was a
feasibility RCT with a three-arm, parallel-group design and 1:1:1
allocation, comparing GiVE and treatment as usual (the study inter-
vention) to supportive counselling and treatment as usual (the
control intervention) to treatment as usual alone, recruiting across
two sites, with blinded post-treatment and follow-up assessments.
Clinical outcomes were assessed at baseline (pre-randomisation,
time point 0), 16 weeks (post-intervention, time point 1) and 28
weeks (follow-up, time point 2; this assessment was only offered
to participants who reached the 28-week post-randomisation mile-
stone before the end of the data collection period). A mixed-
methods process evaluation captured participants’, clinicians’ and
assistant psychologists’ experiences of the study and the interven-
tions, and their views on the facilitators and barriers to the
implementation of GiVE within routine psychosis care pathways.
Findings from the process evaluation will be reported in a separate
paper. There were minimal changes to the design after trial com-
mencement, and details are reported in the study protocol.11 The
trial was registered with the ISRCTN registry (number 16166070)
on 5 February 2019 (http://www.isrctn.com/ISRCTN16166070).
Participants
Participants were recruited over 12 months from community
mental health teams and early intervention in psychosis services
at two sites within the UK National Health Service (NHS): Sussex
Partnership NHS Foundation Trust and Pennine Care NHS
Foundation Trust. Inclusion criteria were: aged 16 years or older
in contact with NHS mental health services and under the care of
a consultant psychiatrist; experiencing current voice hearing
(a score of 1 or more [‘At least once a day’] on item 1 [‘How
frequently did you hear a voice or voices?’] of the Hamilton
Program for Schizophrenia Voices Questionnaire; HPSVQ);11 dis-
tressed by hearing voices (operationalised by participants scoring
at least 8 out of 16 on the negative voice impact scale of the
HPSVQ);12 meeting DSM-5 research criteria for schizophrenia
spectrum or other psychotic disorders (assessed by the Structured
Clinical Interview for DSM-5 disorders13); and willing and able to
provide written informed consent. Exclusion criteria were: estab-
lished organic cause for distressing voices (e.g. brain disease or
injury); primary diagnosis of substance misuse; currently detained
in hospital under a section of the Mental Health Act; have com-
pleted a full course (minimum of 16 h) of CBT for psychosis
during the past year; currently participating, or confirmed to par-
ticipate, in another interventional study in which the participant
is receiving an intervention that utilises psychological therapy;
English speaking to the degree that the participant is unable to
fully understand and answer assessment questions and give
informed consent; severe intellectual disability (assessed with the
Test of Premorbid Functioning –UK)14; and deemed to be at imme-
diate and serious risk to self or others.
Procedure
Following a referral to the research team by a patient’s clinician, a
study research assistant contacted the potential participant to
discuss the study and arrange a consent and eligibility meeting. A
patient information sheet was given to the potential participant at
least 24 h before the meeting. If participants consented to take
part in the study, they completed a baseline (time point 0) assess-
ment at a separate meeting.
The authors assert that all procedures contributing to this work
comply with the ethical standards of the relevant national and insti-
tutional committees on human experimentation and with the
Helsinki Declaration of 1975, as revised in 2008. All procedures
involving patients were approved by an NHS Research Ethics
Committee (London – Surrey, reference number 18/LO/ 2091).
Written informed consent was obtained from all participants.
Intervention description
GiVE
The GiVE intervention was delivered by an assistant psychologist
and followed a workbook8 that was based upon the Overcoming
Distressing Voices self-help book.9 Participants were given a copy
of both the workbook and the self-help book at the commencement
of therapy, and asked to read both and complete the workbook with
the support of the assistant psychologist in sessions. They also had
the opportunity to access the ‘Choices’ mobile phone application, a
publicly available app with interactive elements linked to the
content of the self-help book. GiVE consists of three core
modules: beliefs about the self, beliefs about voices and relationships
with voices and others. There is also an introductory session on
coping with voices and a final session to consolidate learning and
identify next steps. Assistant psychologists delivered GiVE within
eight 1-h sessions, over a maximum of 16 weeks.
Supportive counselling
The supportive counselling intervention followed the therapy
protocol that was used by assistant psychologists in the full RCT
of AVATAR therapy.15 It was delivered over the same number
and duration of sessions as GiVE, with the aim of equalising the dur-
ation of total therapist contact time across both arms. Supportive
counselling offered a supportive and non-judgemental space for
the discussion of topics and issues determined by the participant.
The supportive counselling therapy protocol contained specific
guidance for the assistant psychologist on how to respond to partici-
pant disclosure of distressing voices in a manner that did not
provide specific intervention strategies. The intervention was
delivered within eight 1-h sessions, over a maximum of 16 weeks.
The same assistant psychologists delivered GiVE and supportive
counselling, to minimise therapist effects.
Treatment as usual
Treatment as usual was provided by the usual care team and typic-
ally includedmedication management and support andmonitoring,
with psychological therapies offered occasionally.
Training and supervision
Assistant psychologists received a 5-day training in GiVE and sup-
portive counselling (1 introductory day, 2 days on GiVE and 2 days
on supportive counselling), delivered by clinical psychologists with
experience of CBT for psychosis and an experienced counselling
psychologist, respectively. Weekly clinical supervision was provided
by these clinical psychologists for the GiVE intervention, with a
mixture of 1:1 and group supervision offered face to face or remotely.
The counselling psychologist offered remote group supervision for
the supportive counselling intervention on a weekly basis.
Treatment adherence
Therapeutic drift and contamination were minimised by the use of
highly detailed therapy protocols and close supervision of the assist-
ant psychologists by experienced psychologists. Adherence to
therapy protocols was assessed through assistant psychologists
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completing a checklist at the conclusion of each session. The com-
petence of assistant psychologist delivery of the interventions was
assessed by the rating of a random selection of session recordings
by independent experts. GiVE sessions were rated by a CBT
expert, using the Cognitive Therapy Rating Scale for Psychosis.16
Supportive counselling sessions were rated by a supportive counsel-
ling expert, using the Counselling Adherence Scale.17
Outcomes
Feasibility outcomes prespecified in the published study protocol
were as follows: number of care coordinators willing to refer their
patients, number (percentage) of referred patients found to be
eligible, number (percentage) of consenting participants retained
within the study who offer full data-sets, proportion of non-
missing items for each variable, number (percentage) of consenting
participants within the GiVE and supportive counselling arms who
reach the point of therapy ‘exposure’ (attend at least six out of eight
therapy sessions), and assistant psychologist adherence to therapy
protocols and clinical supervision protocols.
For primary outcomes for a definitive trial, two candidate mea-
sures were used to assess voice-related distress at time points 0, 1
and 2: the five-item distress scale of the Psychotic Symptom Rating
Scales (PSYRATS auditory hallucinations subscale)18 (‘amount of
negative voice content’, ‘degree of negative voice content’, ‘amount
of distress’, ‘intensity of distress’ and ‘controllability of voices’) and
the four-item negative voice impact scale of the HPSVQ11 (‘How
bad are the things voices say to you?’, ‘Howmuch do the voices inter-
fere with your daily activities?’, ‘Howdistressing are the voices that you
hear?’ and ‘How bad do the voices make you feel about yourself?’).
A range of secondary outcomes were assessed at time points 0, 1
and 2, and evaluated mental health problems commonly experienced
by people with psychosis, including anxiety and depression (Hospital
Anxiety and Depression Scale19) and paranoia (Paranoid Thoughts
Scale20); variables that have been associated with the impact of
voice hearing, such as negative beliefs about the self (Self Scale of
the Brief Core Schema Scale)21, negative beliefs about voices
(Beliefs About Voices Questionnaire – Revised22) and negative relat-
ing to voices (Voice and You23) and other people (Persons Relating to
Others Questionnaire24); and a range of personal and social recovery-
oriented outcomes (psychological recovery [CHOICE-SF],25 the posi-
tive impact of voices [Voice Impact Scale] (Strauss C, personal com-
munication, 2018), engagement in meaningful activity [Work and
Social Adjustment Scale]26 and social functioning [Social and
Occupational Functioning Scale]27).
We assessed participants’ expectations for therapy following the
commencement of the intervention between time point 0 and time
point 1 (Therapy Credibility and Expectancy Questionnaire)28 and
the quality of the therapeutic relationships at time point 1 (Scale to
Assess Therapeutic Relationships).29
Health economic outcomes were measured by the EQ-5D-5L,30
the Client Service Receipt Inventory31 and the Short Form 12
Version 2.32
Sample size
Following recommendations for designing feasibility trials that aim
to detect a small-to-medium (Cohen’s d = 0.2–0.5) standardised
effect size (where the definitive trial will be designed with 90%
power and two-sided 5% significance), this study aimed to recruit
90 participants (30 per treatment arm).33–36
Randomisation and blinding
Following the completion of the baseline assessment, participants
were randomly allocated by the trial manager using the Sealed
Envelope online service (https://www.sealedenvelope.com/), incorp-
orating stratification by site (Sussex or Pennine) and type of service
(community mental health team or early intervention in psychosis)
by using random block lengths and 1:1:1 allocation. The online ran-
domisation procedure was set up and tested by the trial statistician.
The research assistants were blind to the allocation sequence
and remained so for all future assessments. Measures were put in
place to maintain blinding, and ‘blind’ awareness and education
was promoted throughout the study. The trial statistician was also
blind to participant allocation throughout the analysis. Reported
breaks in blinding were recorded. Outcome assessments were
re-blinded by re-allocating blind research assistants to collect and
score participant responses.
Statistical analysis
Participant characteristics, feasibility outcomes and baseline clinical
outcomes were summarised with descriptive statistics such as count,
mean, s.d., median, 25% and 75% quartiles, interquartile range,
minimum and maximum. Analyses were of available cases, follow-
ing the intention-to-treat principle. All clinical outcomes were sum-
marised at time points 0, 1 and 2 for each treatment arm. Primary
and secondary outcomes were modelled with linear mixed models
(to allow for covariate adjustment), with random effects for indivi-
duals and fixed effects for treatment group (treatment as usual,
GiVE and supportive counselling), time (time points 1 and 2) and
the group×time interaction with the baseline score, site and
service type entered as covariates. Contrasts were used for the fol-
lowing comparisons: GiVE versus treatment as usual, GiVE versus
supportive counselling, and supportive counselling versus treatment
as usual at time points 1 and 2. 95% and 75% confidence intervals
for all estimates of unstandardised between-group effect sizes
were calculated. For each contrast we were interested in whether
the minimum clinically important difference (MCID) was con-
tained in the confidence interval. The MCIDs are two points for
the HPSVQ negative voice impact scale and three points for the
PSYRATS distress scale. Standardised effect sizes (Cohen’s d)
were also calculated and interpreted as follows: 0.2 = small, 0.5 =
medium and 0.8 = large effect.33 As this was a feasibility study, P-
values from the models are not reported. The level of missing
data was summarised at each time point, but not treated. All ana-
lyses were conducted in Stata (version 16 for Mac).37
Adverse event reporting and harms
Any unfavourable and unintended sign, symptom or illness that
developed or worsened during the period of the study was classified
as an adverse event, whether or not it was considered to be related to
the study treatment and was either expected or unexpected. Serious
adverse events (SAEs) were those considered to be life-threatening.
The number (events and individuals) and nature of all events
(adverse events and SAEs) reported to blind and unblind
members of the research team were recorded. All SAEs were
reviewed for causality and expectedness by an independent rater
and the sponsor’s representative.
Impact of the COVID-19 pandemic
The onset of the pandemic in March 2020 required all assessments
and therapy sessions to be delivered remotely by phone or video call.
At time point 1, 21 out of 68 (31%) assessments were completed
remotely. For time point 2, this figure was 15 out of 46 (33%) assess-
ments. Regarding intervention delivery, 11 participants who were
receiving sessions face to face at the onset of the pandemic were
offered remote sessions (seven for GiVE and four for supportive
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counselling), and a further two participants (one for GiVE and one
for supportive counselling) received all sessions remotely.
Results
Participant flow
A total of 151 patients were referred to the study over a 12-month
period between 13 February 2019 and 24 February 2020. A total
of 101 (66.9%) patients were screened, of whom 79 (78.2%) con-
sented, completed a time point 0 assessment and were randomised
as follows: 27 to treatment as usual, 26 to supportive counselling and
26 to GiVE. Time point 1 and time point 2 assessments were com-
pleted between July 2019 and July 2020. See Fig. 1 for CONSORT
diagram illustrating the flow of participants through the study.
The study was concluded as planned, on 30 August 2020.
The final 6 months of the study were conducted during the
COVID-19 pandemic.
Participant characteristics
There were 45 (57%) male and 34 (43%) female participants, with a
mean age of 40.1 years (s.d. 13.1, range 17–66) and, on average,
had been hearing voices since the age of 22.0 years (s.d. 12.1,
0.1–61). Mean summary scores for the baseline candidate primary
outcomes were 11.6 (s.d. 2.5) for the HPSVQ negative voice
impact scale and 14.5 (s.d. 3.3) for the PSYRATS distress scale.
All baseline participant characteristics and clinical outcomes are
shown in Table 1.
Feasibility outcomes
Aim 1: to assess the acceptability to clinicians of the GiVE intervention
delivered by assistant psychologists (will they refer patients to
the study?)
Patients were referred to the study by 102 different clinicians (50
from the Pennine site and 52 from the Sussex site). Of the 101
patients who consented and were assessed for eligibility, 83 (82%,
95% CI 73.3–89.1%) were found to be eligible. The views of some
of the referring clinicians were explored within the process evalu-
ation and will be reported in a separate paper.
Aim 2: to assess the acceptability to patients of the GiVE intervention
delivered by assistant psychologists (can patients be recruited and
retained, and what are their experiences of the intervention?)
We randomised 79 (88%) of our target of 90 participants. Of those
randomised, 68 (86%) participants completed time point 1 assess-
ments and 46 (74%) participants who reached the 28-week post-
randomisation milestone completed time point 2 assessments.
In terms of therapy exposure, 23 (88%) participants attended at
least six sessions in theGiVE arm (the predetermined level of exposure),
and this was the case for 19 (73%) participants in the supportive coun-
selling arm. The experiences of some of the participants who received
the GiVE and supportive counselling interventions were explored
within the process evaluation and will be reported in a separate paper.
Aim 3: to assess the ability of assistant psychologists to adhere to the
therapy and clinical supervision protocols
All attended sessions of GiVE were self-rated for adherence by
assistant psychologists, using therapy checklists, and adherence
Enrolment Assessed for eligibility (n = 101) 
Time point 0 assessment (n = 83)
Randomised (n = 79)
GiVE (n = 26) Supportive counselling (n = 26) TAU (n = 27)
Completed assessment (n = 22)
Withdrew (n = 1)
Uncontactable (n = 3) 
Declined (n = 3)
Disengaged (n = 1)
Not eligible (n = 16)
Incomplete (n = 2)
Allocation
16 weeks (time point 1)
28 weeks (time point 2)
Completed assessment  (n = 23)
Withdrew (n = 1)
Uncontactable (n = 2)
Completed assessment (n = 23)
Withdrew (n = 2)
Uncontactable (n = 2)
Completed assessment (n = 17)
Assessment not due (n = 5)
Withdrew (n = 3)
Uncontactable (n = 2)
Completed assessment (n = 16)
Assessment not due (n = 5)
Partial completion (n = 2)
Withdrew (n = 3) 
Completed assessment  (n = 13)
Assessment not due (n = 7)
Partial completion (n = 1)
Withdrew (n = 3) 
Uncontactable (n = 2)  
Referred (n = 151)
Unsuitable (n =19)
Declined (n = 31)
Fig. 1 CONSORT flow diagram.
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was indicated for 83% of items. There was some variability by
therapist (range 72–97%) and by session (range 70–88%). For
supportive counselling, all but one attended session was rated by
assistant psychologists and adherence was indicated for 95% of
items. There was some variability in adherence by therapist (range
89–100%) and by session (range 92–97%).
With regard to assistant psychologist competence, the inde-
pendent raters were external to the NHS organisations that were
hosting the trial. Changes to the policies of the NHS organisations
relating to the transfer of patient identifying information created
complexities for the secure transfer of the audio recordings
outside of these organisations. We were not able to overcome
these complexities before the end of the trial. Additionally, during
the COVID-19 pandemic it was not possible to record sessions
delivered remotely because of home working. At the Sussex site,
58 GiVE sessions were recorded (out of a total of 185 sessions
delivered; 31%) and 50 supportive counselling sessions were
recorded (out of a total of 162 sessions delivered; 31%). Six audio
recordings of randomly selected GiVE sessions (3%) from the
Sussex site were independently rated with the Cognitive Therapy
Rating Scale – Psychosis. The mean was 31.7 (s.d. 3.8) out of a
maximum of 60. The mean score for general skills was 17.5
(s.d. 3.1) out of a maximum of 30. The mean score for technical
skills was 14.2 (s.d. 2.1) out of amaximum of 30. The ratings revealed
that although assistant psychologists demonstrated skills in general
understanding and interpersonal skills, they were less able to link ses-
sions though homework and feedback. Ratings were completed for
five supportive counselling sessions (3%) using the Counselling
Adherence Scale, and the mean was 178 (s.d. 2.4) out of a
maximum of 28, which equates to moderate-to-good evidence of
competence. To assess for drift between the interventions, the sup-
portive counselling session recordings were assessed by the
independent CBT rater against the session checklists for the GiVE
intervention. For three of the recordings, the rater found ‘no evidence’
of items from the GiVE checklists. On the remaining two recordings,
there was ‘negligible evidence’ of items from the GiVE checklists.
These assessments suggest that any drift from the GiVE intervention
to the supportive counselling intervention was minimal.
Adherence to clinical supervision protocols was assessed
through the recording of attendance at weekly supervision sessions
for each of the four assistant psychologists. Attendance rates were as
follows: 89.0%, 91.6%, 96.4% and 98.0%.
Completeness of data
Items were mostly at least 90% complete, except for the Scale to
Assess Therapeutic Relationships - Patient version (missing data
was 79% owing to measures not being posted back by participants),
the Therapy Credibility and Expectancy Questionnaire (missing
data was 25%), the Short Form 12 Version 2 (missing data was
53% at time point 0, 92% at time point 1 and 100% at time point
2 [owing to administration errors]), and some of the sociodemo-
graphic characteristics.
Candidate primary outcomes
The descriptive summary for the candidate primary and
selected secondary outcomes at time points 1 and 2 are shown in
Table 2.
Results from the intention-to-treat analyses of the candidate
primary outcomes are shown in Table 3. Details regarding the sec-
ondary outcomes and the health economic outcomes are provided
in the Supplementary material available at https://doi.org/10.1192/
bjo.2021.983.




for voices (n = 26)
Supportive counselling
(n = 26)
Age, years 27; 42.3 (13) 26; 39.6 (11) 26; 38.3 (15)
Gender
Male 19 (70%) 15 (58%) 11 (42%)
Female 8 (30%) 11 (42%) 15 (58%)
Ethnicity
White British/White other 23 (85%) 23 (88.5%) 20 (77%)
Black, Asian and minority ethnic 3 (11%) 3 (11.5%) 4 (15%)
Other 1 (4%) 0 (0%) 2 (8%)
Marital status
Single/separated/divorced 24 (89%) 18 (69%) 20 (81%)
Married/civil partnership/ cohabiting 3 (11%) 8 (31%) 5 (19%)
Employed
Yes 2 (7%) 2 (8%) 1 (4%)
No 25 (93%) 24 (92%) 25 (96%)
Highest education attainment*
None 4 (15%) 8 (31%) 5 (19%)
Secondary school/high school (GCSE or equivalent 7 (26%) 7 (27%) 11 (42%)
College/sixth form 7 (26%) 5 (19%) 5 (19%)
Undergraduate/postgraduate 5 (19%) 5 (19%) 2 (8%)
Other 4 (15%) 1 (4%) 3 (12%)
Age at onset of voice hearing, years 27; 22 (11) 26; 22 (13) 26; 23 (13)
Outcome measures
HPSVQ: negative voice impact (0–16) 27; 11.6 (2.8) 26; 11.6 (2.2) 26; 11.7 (2.4)
PSYRATS: distress (0–20) 27; 14.8 (3.0) 26; 14.8 (2.8) 26; 13.8 (4.1)
HADS: depression (0–21) 27; 11.7 (3.5) 26; 11.7 (3.6) 26; 8.4 (3.4)
HADS: anxiety (0–21) 27; 13.9 (3.8) 26; 13.8 (3.6) 26; 11.6 (4.4)
CHOICE-SF: mean (0–10) 27; 4.0 (1.3) 26; 3.9 (1.6) 26; 4.5 (1.7)
Data are count n (%), mean (s.d.) or n; mean (s.d.). Numbers in brackets after name of the measure is the range of possible values; clinical outcomes are normally distributed. HPSVQ,
Hamilton Program for Schizophrenia Voices Questionnaire; PSYRATS, Psychotic Symptoms Rating Scale; HADS, Hospital Anxiety and Depression Scale; CHOICE-SF, Choice in Outcome in
CBT for Psychoses, Short Form; * some percentage totals may add up to more than 100% due to rounding error.
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All 95% confidence intervals included their respective out-
come’s MCID. For the candidate primary outcomes at time point
1, estimated effects were in favour of GiVE compared with both sup-
portive counselling and treatment as usual. For these comparisons,
Cohen’s d standardised effect sizes ranged frommedium to large. At
time point 2 for HPSVQ negative voice impact: estimated effects
were in favour of supportive counselling compared with both
GiVE (small effect) and treatment as usual (small to medium
effect); effects for GiVE were favourable compared with treatment
as usual (small effect). For PSYRATS distress at time point 2: esti-
mated effects were in favour of GiVE compared with both support-
ive counselling (negligible effect) and treatment as usual (medium
effect); supportive counselling was favourable to treatment as
usual (small to medium effect).
Breaks in blinding
One break in blinding was reported. In this instance, the assessment
was completed by a blinded researcher who was not part of the
research team.
Assessment of safety
SAEs were reported by 11 participants on a total of 16 occasions.
The most frequently recorded SAE code was ‘suicidal ideation
and intent to act’ (3). The SAEs were distributed evenly across the
three arms. Independent assessment suggested that no SAEs were
related to the trial or its procedures. Adverse events were reported
by 20 participants on a total of 30 occasions. The most frequently
recorded adverse event codes were ‘deterioration in mental health’
(n = 10), ‘general medical assessment/procedure’ (n = 8), ‘suicidal
ideation’ (n = 6) and ‘self-harm’ (n = 4). The adverse events were
evenly distributed across the three arms.
Discussion
This study has demonstrated that a definitive RCT of the GiVE
intervention delivered by assistant psychologists to patients with
psychosis is feasible. Clinicians were willing to refer their patients,
the majority of participants completed interventions and were
retained at follow-up, and assistant psychologists were adherent
to therapy and supervision protocols. The interventions appeared
to be safe and the MCIDs for the candidate primary outcomes
were captured in the 95% confidence intervals for the between-
group differences in the means at time point 1.
The favourable levels of referrals and recruitment suggest a will-
ingness on behalf of clinicians and patients with psychosis to engage
with a trial when the intervention is delivered by briefly trained
assistant psychologists. Once randomised, participants demon-
strated further willingness to engage in the study by attending
therapy sessions and time point 1 assessments. The level of
therapy exposure was highest for the participants receiving the
GiVE intervention (88%), with an exposure rate higher than com-
parable trials where CBT for psychosis was delivered by highly
trained therapists (e.g. 72%38). Attendance at time point 2 assess-
ments was lower than at time point 1. Although noteworthy,
Table 2 Summary of candidate primary (HPSVQ & PSYRATS) and secondary clinical outcomes by group at time points 1 and 2
Clinical outcome (range)
Treatment as usual (n = 27
randomised), n; mean (s.d.)
Guided self-help intervention for voices
(n = 26 randomised), n; mean (s.d.)
Supportive counselling (n = 26
randomised), n; mean (s.d.)
Time point 1 HPSVQ: negative voice
impact (0–16)
23; 10.2 (4.6) 22; 8.1 (4.0) 23; 10.0 (4.1)
PSYRATS: distress (0–20) 23; 13.6 (4.7) 22; 11.8 (5.4) 22; 14.0 (4.2)
HADS: depression (0–21) 23; 11.1 (4.9) 22; 8.9 (3.6) 23; 8.6 (4.6)
HADS: anxiety (0–21) 23; 13.1 (4.1) 22; 11.9 (4.4) 23; 11.6 (4.0)
CHOICE-SF: mean (0–10) 23; 3.9 (1.8) 22; 5.6 (2.1) 23; 5.2 (2.2)
Time point 2 HPSVQ: negative voice
impact (0–16)
14; 9.5 (2.3) 12; 9.2 (5.0) 17; 8.4 (5.2)
PSYRATS: distress (0–20) 15; 14.3 (2.4) 12; 13.0 (4.8) 16; 12.4 (4.3)
HADS: depression (0–21) 15; 10.5 (3.8) 12; 10.0 (5.0) 16; 7.4 (4.4)
HADS: anxiety (0–21) 15; 11.9 (4.4) 12; 11.3 (4.2) 16; 10.0 (5.9)
CHOICE-SF: mean (0–10) 15; 4.2 (1.7) 12; 4.8 (2.5) 16; 5.6 (2.7)
HPSVQ, Hamilton Program for Schizophrenia Voices Questionnaire; PSYRATS, Psychotic Symptoms Rating Scale; HADS, Hospital Anxiety and Depression Scale; CHOICE-SF, Choice in
Outcome in CBT for Psychoses, Short Form.
Table 3 Effect sizes for candidate primary outcomes by time point
Clinical outcome Pairwise comparison

















GiVE versus TAU −1.75 1.13 −3.96 0.46 −0.71 −0.37 1.37 −3.06 2.32 −0.15
Supportive counselling
versus TAU
0.08 1.11 −2.09 2.25 0.03 −1.01 1.28 −3.51 1.50 −0.41
GiVE versus supportive
counselling
−1.83 1.12 −4.02 0.36 −0.75 0.64 1.33 −1.96 3.24 0.26
PSYRATS: distress GiVE versus TAU −1.63 1.19 −3.97 0.72 −0.49 −1.66 1.45 −4.50 1.18 −0.50
Supportive counselling
versus TAU
0.92 1.21 −1.45 3.29 0.28 −1.44 1.38 −4.14 1.27 −0.44
GiVE versus supportive
counselling
−2.54 1.20 −4.90 −0.19 −0.77 −0.22 1.43 −3.03 2.59 −0.07
Table provides results of pairwise comparisons of intervention [A] versus [B] at time point 1/time point 2. Effect estimates represent a difference in change for [A] comparedwith [B]: negative
scores indicate that [A] has improved more and positive scores indicate that [B] has improved more. For Cohen’s d calculations, HPSVQ s.d. = 2.46 and PSYRATS s.d. = 3.30. LCL, lower
confidence limit; UCL, upper confidence limit; HPSVQ, Hamilton Program for Schizophrenia Voices Questionnaire; GiVE, guided self-help intervention for voices; TAU, treatment as usual;
PSYRATS, Psychotic Symptoms Rating Scale.
a. Conventions for interpreting Cohen’s d are as follows: 0.2 = small effect, 0.5 =medium effect and 0.8 = large effect.33
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attempts were made to engage only a subset of participants
(as planned) in the time point 2 assessments, and the limited
attendance may, in part, be attributable to the COVID-19 pan-
demic, which led to all assessments being conducted remotely
during the final 6 months of data collection.
Willingness to engage with the trial was also required by the
other important stakeholder group – the assistant psychologists.
To our knowledge, no studies have previously explored the adher-
ence of this workforce to therapy and supervision protocols when
working with patients with psychosis. Consequently, rigorous
assessment was required. Findings were encouraging, with each of
the assistant psychologists attending most of the weekly clinical
supervision sessions offered. Self-rated adherence to the therapy
protocols was also high, but with variation across particular sessions
indicating areas for additional training within a future trial. The
rating of competence was restricted by the limited availability of
session recordings as a result of information governance issues
and the COVID-19 pandemic. The former issues will need to be
addressed before a future trial. The available ratings suggested
that assistant psychologists could achieve competence in the deliv-
ery of both GiVE and supportive counselling. However, the ratings
for the GiVE intervention suggested some areas for improvement,
including the linking of learning during and between sessions,
which could be addressed in a future trial with specific training
and supervision on this issue. The assessment of contamination
between the interventions suggested that the assistant psychologists
had been able to prevent the GiVE techniques from drifting into the
supportive counselling sessions.
Findings were also encouraging with respect to the candidate
primary outcomes. Medium-to-large estimated effects were found
in favour of GiVE compared with both supportive counselling
and treatment as usual at time point 1. The effect sizes were in
line with prior expectations of detecting small-to-medium effects
with some inflation owing to the small sample size. Although
effects detected in small feasibility studies, such as this one, are
likely to be imprecise and biased, the size and magnitude of our
detected effects support further testing in a powered RCT. The find-
ings at time point 2 were less clear as the estimated effects favoured
supportive counselling compared with GiVE and treatment as usual
with (negligible-small and medium effects, respectively). However,
GiVE was still favourable compared with treatment as usual negli-
gible-medium effects at time point 2. The findings at time point 2
were attributable, in part, to a reduction of benefits for GiVE
during the follow-up period (from time point 1 to time point 2),
and may indicate the need for the intervention to be extended
and/or for the addition of booster sessions. This reduction in
benefit for GiVE during the follow-up period also raises the ques-
tion of the potential place of this intervention within a therapeutic
pathway for patients with psychosis, e.g. as part of a modular
pathway where other single-symptom interventions could build
upon the learning generated by GiVE, or vice versa. A modular
pathway for the psychological treatment of paranoia has recently
been evaluated and generated encouraging findings, albeit with
the interventions delivered by highly trained therapists.39 The find-
ings of increased benefits for supportive counselling during the
follow-up period are similar to those reported by the recently com-
pleted RCT of AVATAR therapy.14 Those authors suggested that
supportive counselling is a control condition with non-specific
factors that, compared with treatment as usual, can be effective in
its own right. This is a possibility that is worthy of further
investigation.
This study has limitations in a number of respects. First, the
follow-up data were available for only a subsample of the partici-
pants (as planned), thereby limiting the learning about the durabil-
ity of benefits from the interventions. Second, the self-reported
adherence ratings of the assistant psychologists were not assessed
and would benefit from independent assessment within a future
trial. Furthermore, the competence ratings of the assistant psychol-
ogists were limited to a small selection of session recordings. Further
learning about the competence of assistant psychologists within a
future trial will be crucial, and any barriers to the rating of compe-
tence must be addressed a priori. Finally, the findings may have
been influenced by the COVID-19 pandemic. Some of the therapy
sessions and assessments were conducted remotely during the
final 6 months of the study, but any impact of remote delivery
and/or the more general impact of the pandemic upon participants
could not be established because of the small sample size.
The main implication of this trial is that a definitive RCT is feas-
ible and is now required to provide evidence regarding the efficacy
of a brief, CBT-informed intervention for distressing voices when
delivered to patients with psychosis by assistant psychologists. If
found to be efficacious in future trials, CBT for psychosis offered
in these less resource-intensive forms has the potential to generate
benefits for individual patients (reduced distress and enhanced
recovery), service-level patient benefits (increased access to evi-
dence-based psychological therapies) and economic benefits to
the NHS (in terms of the reduced use of high-impact mental
health services).
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